TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06261203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
Study: NCT06178432

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CRG003 injection
Description: The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
Study: NCT05882045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05849337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief imagery-competing task
Description: Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychoeducation and signposting task
Description: Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Routine care that participants would otherwise receive if having intrusive memories of traumatic events
Study: NCT06345066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.
Study: NCT06321640

Intervention type: GENETIC
Intervention: Cohort A: primarily operable disease, candidate to adjuvant
Description: This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint

Intervention type: GENETIC
Intervention: Cohort B: locally advanced disease
Description: Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.

Intervention type: GENETIC
Intervention: Cohort C: metastatic disease
Description: In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.

Intervention type: GENETIC
Intervention: Cohort D: Progressive disease
Description: In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.

Intervention type: GENETIC
Intervention: Cohort E: Hematological neoplasms
Description: Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.

Intervention type: GENETIC
Intervention: Cohort F: Toxicity
Description: In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
Study: NCT05218538

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan (non interventional)
Description: An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan (non interventional)
Description: An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
Study: NCT05904197

Intervention type: OTHER
Group type: OTHER
Intervention: Gamified Cards about Nephrotic Syndrome
Description: * The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication...etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child.
Study: NCT05845151

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET
Description: Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
Study: NCT06110611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech Osseospeed EV® dental implant
Description: Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
Study: NCT05183646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMX-200
Description: DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 120 mg capsules of Placebo twice daily
Study: NCT06067724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic and trunk control exercises
Description: Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
Study: NCT06345066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC.
Study: NCT06067724

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pelvic and trunk control exercises
Description: Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
Study: NCT06086782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic inhibition
Description: Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reciprocal inhibition
Description: Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
Study: NCT06022146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin and Isoniazid
Description: 3HR regimen of isoniazid and rifampicin once daily for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid and rifapentine
Description: 12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
Study: NCT04973085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold circulated water
Description: Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
Study: NCT06264401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: control group received (Alendronate) 70 mg 1 tab every week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: control group received (Alendronate) 70 mg 1 tab every week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment exercises
Description: the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
Study: NCT05338216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional EMA
Description: Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Micro-Interaction EMA
Description: Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day.
Study: NCT05063604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 20 mg tablet one or twice daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: One session weekly for 12 weeks
Study: NCT06345066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT06481163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telacebec
Description: The test product will be supplied as Telacebec 100mg tablets.
Study: NCT04905069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceOAR Vue System
Description: The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
Study: NCT05453578

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 percent sodium chloride
Study: NCT05369637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Nutrition education
Description: This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis and correction of hearing impairment
Description: This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
Study: NCT04973085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body-temperature circulated water
Description: Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
Study: NCT06009861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Study: NCT05658419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket sheild
Description: the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket sheild
Description: the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
Study: NCT06411678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68GA-DOTA-dPNE
Description: Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
Study: NCT04173390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
Study: NCT05859906

Intervention type: OTHER
Intervention: mechanical power measurement
Description: Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]

Intervention type: OTHER
Intervention: mechanical power measurement
Description: Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]
Study: NCT06056037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Making ART Work
Description: A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
Study: NCT06162936

Intervention type: DIAGNOSTIC_TEST
Intervention: Phagoburst
Description: The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.